Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.

被引：0
|
作者：
Ghobrial, Irene M. [1 ]
Munshi, Nikhil [1 ]
Schlossman, Robert [1 ]
Chuma, Stacey [1 ]
Leduc, Renee [1 ]
Nelson, Marybeth [1 ]
Sam, Amy [1 ]
O'Connor, Kelly [1 ]
Harris, Brianna [1 ]
Warren, Diane [1 ]
Dollard, Akari M. [2 ]
Laubach, Jacob [1 ]
Vij, Ravi [3 ]
Campagnaro, Erica [4 ]
Birner, Ann [5 ]
Dixon-Lipscomb, Virginia
Anderson, Kenneth C. [1 ]
Richardson, Paul G. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] MMRC, Norwalk, CT USA
[3] Washington Univ, St Louis, MO USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1266 / 1266
页数：1
相关论文
共 50 条
  • [1] Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
    Roccaro, A. M.
    Leduc, R.
    Nelson, M.
    Sam, A.
    Chuma, S.
    Colson, K.
    O'Connor, K.
    Ghobrial, I. M.
    Munshi, N. C.
    Schlossman, R.
    Harris, B.
    Warren, D.
    Dollard, A. M.
    Laubach, J.
    Vij, R.
    Campagnaro, E.
    Birner, A.
    Dixon-Lipscomb, V.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S86 - S86
  • [2] Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Vij, Ravi
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Laubach, Jacob
    Campagnaro, Erica L.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2009, 114 (22) : 311 - 312
  • [3] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Rourke, Meghan
    Schlossman, Robert L.
    Laubach, Jacob P.
    Jakubowiak, Andrzej J.
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 435 - 436
  • [4] Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
    Hofmeister, Craig C.
    Benson, Don
    Efebera, Yvonne A.
    Farag, Sherif
    Grever, Michael R.
    BLOOD, 2009, 114 (22) : 1126 - 1126
  • [5] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
    Farag, S. S.
    Zhang, S.
    Miller, M.
    Buckner, M.
    Kraut, E.
    Chan, K.
    Eng, C.
    Byrd, J. C.
    Dancey, J. E.
    Grever, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [6] LENALIDOMIDE AND CCI-779 TREATMENT FOR RELAPSED MULTIPLE MYELOMA
    不详
    CANCER DISCOVERY, 2011, 1 (04) : 283 - 283
  • [7] Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
    Hofmeister, Craig C.
    Yang, Xiaoxia
    Pichiorri, Flavia
    Chen, Ping
    Rozewski, Darlene M.
    Johnson, Amy J.
    Lee, Seungsoo
    Liu, Zhongfa
    Garr, Celia L.
    Hade, Erinn M.
    Ji, Jia
    Schaaf, Larry J.
    Benson, Don M., Jr.
    Kraut, Eric H.
    Hicks, William J.
    Chan, Kenneth K.
    Chen, Ching-Shih
    Farag, Sherif S.
    Grever, Michael R.
    Byrd, John C.
    Phelps, Mitch A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3427 - 3434
  • [8] A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
    Lonial, Sagar
    Francis, Dixil
    Karanes, Chatchada
    Trudel, Suzanne
    Dollard, Akari M.
    Aceo, Fermin
    Gul, Engin
    Kakar, Sumeet
    Krishnan, Amrita Y.
    Reece, Donna E.
    Harvey, R. Donald
    Kaufman, Jonathan L.
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [9] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, TE
    Geyer, SM
    Ghobrial, I
    Inwards, DJ
    Fonseca, R
    Kurtin, P
    Ansell, SM
    Luyun, R
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, H
    Kaufmann, SH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
  • [10] Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.
    Suvannasankha, A
    Smith, GG
    Abonour, R
    BLOOD, 2005, 106 (11) : 720A - 720A
12345